Cargando…

Funding global health product R&D: the Portfolio-To-Impact Model (P2I), a new tool for modelling the impact of different research portfolios

Background: The Portfolio-To-Impact (P2I) Model is a novel tool, developed to estimate minimum funding needs to accelerate health product development from late stage preclinical study to phase III clinical trials, and to visualize potential product launches over time. Methods: A mixed methods approa...

Descripción completa

Detalles Bibliográficos
Autores principales: Terry, Robert F, Yamey, Gavin, Miyazaki-Krause, Ryoko, Gunn, Alexander, Reeder, John C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000 Research Limited 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6139376/
https://www.ncbi.nlm.nih.gov/pubmed/30234194
http://dx.doi.org/10.12688/gatesopenres.12816.2
_version_ 1783355505833410560
author Terry, Robert F
Yamey, Gavin
Miyazaki-Krause, Ryoko
Gunn, Alexander
Reeder, John C.
author_facet Terry, Robert F
Yamey, Gavin
Miyazaki-Krause, Ryoko
Gunn, Alexander
Reeder, John C.
author_sort Terry, Robert F
collection PubMed
description Background: The Portfolio-To-Impact (P2I) Model is a novel tool, developed to estimate minimum funding needs to accelerate health product development from late stage preclinical study to phase III clinical trials, and to visualize potential product launches over time. Methods: A mixed methods approach was used. Assumptions on development costs at each phase were based on clinical trial costs from Parexel’s R&D cost sourcebook. These were further refined and validated by interviews, with a wide variety of stakeholders from Product Development Partnerships, biopharmaceutical and diagnostic companies, and major funders of global health R&D. Results: the tool was used to create scenarios describing the impact, in terms of products developed, of different product portfolios with funding ranging from $1 million per annum through to $500 million per annum. These scenarios for a new global financing mechanism have been previously presented in a report setting out the potential for a new fund for research and development which would assist in accelerating product development for the diseases of poverty.  Conclusion: The P2I tool does enable a user to model different scenarios in terms of cost and number of health products launched when applied to a portfolio of health products.  The model is published as open access accompanied with a user guide.  The design allows it to be adapted and used for other health R&D portfolio analysis as described in an accompanying publication focussing on the pipeline for neglected diseases in 2017. We aim to continually refine and improve the model and we ask users to provide us with their own inputs that can help us update key parameters and assumptions.  We hope to catalyse users to adapt the model in ways that can increase its value, accuracy, and applications.
format Online
Article
Text
id pubmed-6139376
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher F1000 Research Limited
record_format MEDLINE/PubMed
spelling pubmed-61393762018-09-17 Funding global health product R&D: the Portfolio-To-Impact Model (P2I), a new tool for modelling the impact of different research portfolios Terry, Robert F Yamey, Gavin Miyazaki-Krause, Ryoko Gunn, Alexander Reeder, John C. Gates Open Res Research Article Background: The Portfolio-To-Impact (P2I) Model is a novel tool, developed to estimate minimum funding needs to accelerate health product development from late stage preclinical study to phase III clinical trials, and to visualize potential product launches over time. Methods: A mixed methods approach was used. Assumptions on development costs at each phase were based on clinical trial costs from Parexel’s R&D cost sourcebook. These were further refined and validated by interviews, with a wide variety of stakeholders from Product Development Partnerships, biopharmaceutical and diagnostic companies, and major funders of global health R&D. Results: the tool was used to create scenarios describing the impact, in terms of products developed, of different product portfolios with funding ranging from $1 million per annum through to $500 million per annum. These scenarios for a new global financing mechanism have been previously presented in a report setting out the potential for a new fund for research and development which would assist in accelerating product development for the diseases of poverty.  Conclusion: The P2I tool does enable a user to model different scenarios in terms of cost and number of health products launched when applied to a portfolio of health products.  The model is published as open access accompanied with a user guide.  The design allows it to be adapted and used for other health R&D portfolio analysis as described in an accompanying publication focussing on the pipeline for neglected diseases in 2017. We aim to continually refine and improve the model and we ask users to provide us with their own inputs that can help us update key parameters and assumptions.  We hope to catalyse users to adapt the model in ways that can increase its value, accuracy, and applications. F1000 Research Limited 2018-07-19 /pmc/articles/PMC6139376/ /pubmed/30234194 http://dx.doi.org/10.12688/gatesopenres.12816.2 Text en Copyright: © 2018 Terry RF et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Terry, Robert F
Yamey, Gavin
Miyazaki-Krause, Ryoko
Gunn, Alexander
Reeder, John C.
Funding global health product R&D: the Portfolio-To-Impact Model (P2I), a new tool for modelling the impact of different research portfolios
title Funding global health product R&D: the Portfolio-To-Impact Model (P2I), a new tool for modelling the impact of different research portfolios
title_full Funding global health product R&D: the Portfolio-To-Impact Model (P2I), a new tool for modelling the impact of different research portfolios
title_fullStr Funding global health product R&D: the Portfolio-To-Impact Model (P2I), a new tool for modelling the impact of different research portfolios
title_full_unstemmed Funding global health product R&D: the Portfolio-To-Impact Model (P2I), a new tool for modelling the impact of different research portfolios
title_short Funding global health product R&D: the Portfolio-To-Impact Model (P2I), a new tool for modelling the impact of different research portfolios
title_sort funding global health product r&d: the portfolio-to-impact model (p2i), a new tool for modelling the impact of different research portfolios
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6139376/
https://www.ncbi.nlm.nih.gov/pubmed/30234194
http://dx.doi.org/10.12688/gatesopenres.12816.2
work_keys_str_mv AT terryrobertf fundingglobalhealthproductrdtheportfoliotoimpactmodelp2ianewtoolformodellingtheimpactofdifferentresearchportfolios
AT yameygavin fundingglobalhealthproductrdtheportfoliotoimpactmodelp2ianewtoolformodellingtheimpactofdifferentresearchportfolios
AT miyazakikrauseryoko fundingglobalhealthproductrdtheportfoliotoimpactmodelp2ianewtoolformodellingtheimpactofdifferentresearchportfolios
AT gunnalexander fundingglobalhealthproductrdtheportfoliotoimpactmodelp2ianewtoolformodellingtheimpactofdifferentresearchportfolios
AT reederjohnc fundingglobalhealthproductrdtheportfoliotoimpactmodelp2ianewtoolformodellingtheimpactofdifferentresearchportfolios